MMP9 and glioblastoma: In a retrospective analysis performed in the Avaglio trial (a randomised phase III trial that compared bevacizumab versus placebo in addition to standard of care in newly diagnosed glioblastoma patients), a low plasma level of MMP-9 at baseline consistently predicted PFS and OS gain associated to bevacizumab [39].